Gufic BioScience Q1 FY27 Results (NSE: GUFICBIO)
Signal: Margin expansion
The read
Q1FY27 marks a meaningful operating inflection after three consecutive quarters of YoY margin contraction: consolidated EBITDA margin recovered to 18% from 15% a year ago, EBITDA grew 37.5% versus revenue growth of 16.6%, and PAT rose 70.7% to ₹2231.28 lakh. The recovery was supported by raw-material and inventory cost falling to 44.1% of revenue from 45.0%, while finance cost grew only 0.9%; however, margin eased 100bps sequentially from Q4FY26's 19%, so durability of the rebound remains the central trajectory question.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹260.82 Cr | 16.6% | +3.6% |
| EBIT | ₹39.36 Cr | 48.5% | |
| Net profit | ₹22.31 Cr | 70.7% | |
| EPS | ₹2.22 | 70.8% | |
| EBIT margin | 18% |
P&L walk
Consolidated revenue rose to ₹26081.80 lakh (+16.6% YoY, +3.6% QoQ), while the lower raw-material and inventory-cost ratio supported EBITDA of ₹4706.00 lakh (+37.5% YoY) and an 18% margin; PAT increased to ₹2231.28 lakh (+70.7%), with other income of only ₹45.75 lakh.
Segments
The company reports a single operating segment, Pharmaceuticals; standalone PAT of ₹2246.05 lakh was ₹14.77 lakh above consolidated PAT of ₹2231.28 lakh, indicating only a modest subsidiary drag.
Key positives
- Consolidated EBITDA rose 37.5% YoY to ₹4706.00 lakh versus revenue growth of 16.6%, a +20.9 percentage-point growth gap, while EBITDA margin expanded 300bps to 18%.
- Employee benefits expense grew 16.1% YoY and other expenses grew 7.0% YoY, both below revenue growth, supporting the 300bps EBITDA-margin recovery.
- Raw-material, purchase and inventory-cost consumption declined to 44.1% of revenue from 45.0% a year ago, providing a 90bps gross-margin improvement; the filing does not disclose whether this reflects pricing, input costs or mix.
- PAT rose 70.7% to ₹2231.28 lakh and EPS rose 70.8% to ₹2.22, with EPS tracking PAT and other income limited to ₹45.75 lakh.
- The proposed Philippines subsidiary targets marketing, sale and distribution of pharmaceutical products and is expected to be incorporated within 12 months, subject to approvals.
Key concerns
- Consolidated EBITDA margin of 18% was still 100bps below Q4FY26's 19%, so the sharp YoY recovery has not yet established a new sequential margin trend.
- Revenue growth was 16.6% YoY on a consolidated basis but standalone growth was 14.9%, and the filing provides no volume, geography or product-mix disclosure to validate the growth quality.
Research and educational content only. Not investment advice.